Suppr超能文献

Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence.

作者信息

Rosset Francois, Sciamarrelli Nadia, Mastorino Luca, Pala Valentina, Boskovic Sara, Bongiovanni Eleonora, Crespi Orsola, Liao Yingying, Ribero Simone, Quaglino Pietro

机构信息

School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy.

出版信息

Antibodies (Basel). 2025 Sep 17;14(3):79. doi: 10.3390/antib14030079.

Abstract

Lichen planus (LP) is a chronic inflammatory disease of autoimmune origin, affecting the skin and mucous membranes. While corticosteroids and immunosuppressants are traditionally used, many cases remain refractory or intolerant to standard therapies. Recent advances in immunopathogenesis have led to the exploration of targeted therapies, including biologic agents and small-molecule inhibitors. This review synthesizes current evidence from case reports, case series, and observational studies on the use of monoclonal antibodies (anti-TNF-α, anti-IL-17, anti-IL-23, anti-IL-6) and JAK inhibitors in LP. A structured literature search was conducted across PubMed, Scopus, and Web of Science, focusing on studies published between 2010 and 2025. Data on mechanisms, clinical efficacy, safety, and research limitations were extracted and summarized. Promising therapeutic responses were reported for IL-17 inhibitors (secukinumab, ixekizumab) and JAK inhibitors (tofacitinib, baricitinib) in mucosal and recalcitrant LP. Anti-TNF agents showed variable efficacy, while emerging targets such as BTK and IFN-γ are under investigation. Adverse events were generally mild to moderate, but long-term safety data are lacking. The absence of randomized controlled trials and standardized outcome measures limits generalizability. Biologic and small-molecule therapies represent a potential paradigm shift in the treatment of LP, offering targeted immunomodulation with promising efficacy in refractory cases. Further collaborative research, including randomized studies and biomarker-driven approaches, is urgently needed to validate these treatments and establish personalized care strategies.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae78/12452788/090abd7b4028/antibodies-14-00079-g001.jpg

相似文献

2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
4
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2025 Aug 6;8(8):CD011535. doi: 10.1002/14651858.CD011535.pub7.
8
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.

本文引用的文献

2
IL-23 inhibition for chronic inflammatory disease.
Lancet. 2024 Oct 26;404(10463):1679-1692. doi: 10.1016/S0140-6736(24)01750-1.
4
The potential of Bruton's tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease.
Expert Opin Pharmacother. 2024 Aug;25(12):1657-1665. doi: 10.1080/14656566.2024.2393280. Epub 2024 Sep 3.
5
BTK inhibitors: past, present, and future.
Trends Pharmacol Sci. 2024 Aug;45(8):691-707. doi: 10.1016/j.tips.2024.06.006. Epub 2024 Jul 17.
6
Lichen Planus: What is New in Diagnosis and Treatment?
Am J Clin Dermatol. 2024 Sep;25(5):735-764. doi: 10.1007/s40257-024-00878-9. Epub 2024 Jul 9.
8
Assessment of PD-1 and PD-L1 tissue expression levels in lichen planus patients: a case-control study.
Arch Dermatol Res. 2024 Mar 2;316(3):97. doi: 10.1007/s00403-024-02838-z.
9
What can we learn from treatments of oral lichen planus?
Front Cell Infect Microbiol. 2024 Feb 15;14:1279220. doi: 10.3389/fcimb.2024.1279220. eCollection 2024.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验